Navigation Links
PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
Date:8/20/2007

tial thrombosis increases the relative risk of death by five- to ten-fold for PNH patients.(3,7) Thrombosis is related to hemolysis in patients with PNH, and patients with both smaller and larger PNH clones are reported to experience this complication.(8,9,10,11,12) Research involving a small group of PNH patients, including those without a history of blood transfusion, found that 60 percent had sub-clinical thrombosis, which could later develop into blood clots.(13)

"For decades, people with PNH have lived with debilitating symptoms, including the threat of blood clots and their complications," said Leonard Bell, MD, Chief Executive Officer of Alexion. "This publication reinforces the importance of our goal to ensure that every PNH patient who can benefit from Soliris will have access to it."

"Many PNH patients face not only devastating symptoms, but a sharply increased risk for developing life-threatening blood clots as a result of their disease," said John Huber, Executive Director of the Aplastic Anemia & MDS International Foundation. "This news provides additional hope for patients struggling with PNH and the danger of PNH-related blood clots. We look forward to seeing the impact this new analysis has on treatment of patients with PNH."

Clinical Data

The publication, titled "Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria," analyzed data from 195 patients studied in the Soliris Phase II and Phase III trials, including the TRIUMPH and SHEPHERD studies. Patients were enrolled in the United States, Europe, Australia and Canada and treated with Soliris for up to 54 months. Soliris reduced hemolysis in all treated patients and reduced thrombosis by 92 percent, with three events during Soliris treatment compared to 39 events during the same period of time prior to treatment (P<0.0001). The collection of thrombotic events was defined prospectively by clinical trial protocols.
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
2. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
3. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
4. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
5. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
6. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
7. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
8. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
9. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
10. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
11. Skin Rash Actually Signifies Better Outcomes for Pancreatic and Lung Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 ... has announced the addition of the "Investigation ... to their offering. Originally discovered by ... Yoshitomi Pharmaceutical Industries, Ltd) as an inflammatory drug, ... Senju Pharmaceutical Co., Ltd under the trade name ...
(Date:8/28/2015)... -- Research and Markets ( ... "12th Annual Report and Survey of Biopharmaceutical ... offering. The 2015 12th Annual Report ... is the most recent study of biotherapeutic developers ... capacity and production. The report contains the industry,s ...
(Date:8/28/2015)... , Aug. 28, 2015  Today, in final ... (CDC) Contact Lens Health Week, 1-800 Contacts is sharing ... found that contact lens wearers who do not properly ... risk for eye infections. Most contact ... lenses, but a clean lens case is sometimes overlooked.  ...
Breaking Medicine Technology:Investigation Report on China's Pranoprofen Market, 2010-2019 212th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 21-800 Contacts Shares Tips on How to Clean Lens Cases 2
... August 21 The medicated pain relief ... Medicines Consortium (SMC) for,restricted use within NHS ... http://www.scottishmedicines.org.uk/smc/5850.html . This,reversal of the previous SMC ... lidocaine medicated plaster) is based on significant ...
... Aug. 21 Johnson & Johnson Pharmaceutical,Research ... the U.S. Food,and Drug Administration (FDA) requires ... New Drug Application (NDA) for DORIBAX(TM),(doripenem for ... known as nosocomial pneumonia (NP), including ventilator-associated,pneumonia ...
Cached Medicine Technology:Shingles Pain Treatment Will Benefit More Patients 2Shingles Pain Treatment Will Benefit More Patients 3Shingles Pain Treatment Will Benefit More Patients 4FDA Requires Additional Information on DORIBAX for Treatment of Hospital-Acquired Pneumonia 2FDA Requires Additional Information on DORIBAX for Treatment of Hospital-Acquired Pneumonia 3FDA Requires Additional Information on DORIBAX for Treatment of Hospital-Acquired Pneumonia 4FDA Requires Additional Information on DORIBAX for Treatment of Hospital-Acquired Pneumonia 5
(Date:8/28/2015)... TX (PRWEB) , ... August 28, 2015 , ... For ... Center is taking part with their subsidiary USPI Tenet Health. , The American Heart ... fight heart disease and stroke. They believe that together, a difference can be made. ...
(Date:8/28/2015)... Hanover, MA (PRWEB) , ... August 28, 2015 , ... ... benefitting the renowned Brain Aneurysm Foundation has added yet another accolade to its ... Chicago, Rahm Emanuel. , “With the help of the medical community and ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... high grade protein with zero fat, carbs, sugar, gluten, lactose or caffeine in ... finalist for the 2015 SupplySide CPG Editor’s Choice Awards. , Five consumer packaged ...
(Date:8/28/2015)... Boynton Beach, FL. (PRWEB) , ... August 28, ... ... creating problems for businesses nationwide. Addictions specialist, Dr. James Strawbridge, gives a new ... Strawbridge believes that it should begin with the employer and employees getting together ...
(Date:8/28/2015)... ... August 28, 2015 , ... CARF ... its adolescent residential, counseling, day treatment and intensive family based services. , By ... for quality and its pursuit of excellence. As a nonprofit charity for more ...
Breaking Medicine News(10 mins):Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 3Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3Health News:West Ridge Academy Awarded CARF Three-Year Accrediation 2
... learn whether protein supplements and cycling during treatments can ... function, thanks to a $2.1 million grant from the ... failure face many health problems. They are at high ... and they also develop a peculiar condition called vascular ...
... a model of stroke A team of researchers, led ... identified a way to preserve nerve cells in a rat model ... of oxygen to part of the brain as a result of ... leads to nerve cell death, although the exact mechanisms underlying ischemic ...
... shoulder muscles in elderly patients is often discouraged because of ... Rush University Medical Center has shown that minimally invasive, or ... study has just been published online in Arthroscopy: ... appear in the October issue. "In people over the ...
... study of Ewing,s sarcoma that screened hundreds of genes based ... anti-cancer drug targets, according to a scientific paper by the ... journal Molecular Cancer . Ewing,s sarcomas are rare, ... bones of teenagers. They represent nearly 3 percent of all ...
... the probability of dying in road accidents on the basis ... Their conclusions are clear reducing the time between an ... from 25 to 15 minutes would cut the risk of ... until the emergency medical services arrive is 25 minutes in ...
... Faith based schools are on the rise in ... values at odds with legislation on equality? Research that ... Leadership published by SAGE shows what happens when school ... consequences for gay students and staff. The UK ...
Cached Medicine News:Health News:Will extra protein and exercise help dialysis patients? U of I profs get $2.1 million to find out 2Health News:Will extra protein and exercise help dialysis patients? U of I profs get $2.1 million to find out 3Health News:JCI online early table of contents: Sept. 1, 2010 2Health News:JCI online early table of contents: Sept. 1, 2010 3Health News:JCI online early table of contents: Sept. 1, 2010 4Health News:JCI online early table of contents: Sept. 1, 2010 5Health News:JCI online early table of contents: Sept. 1, 2010 6Health News:Surgery to repair torn shoulder muscles in the elderly can reduce pain and improve function 2Health News:TGen finds therapeutic targets for rare cancer in children 2Health News:10 minutes could prevent one-third of road deaths 2Health News:Keeping faith -- schools must balance ethos with equality 2
TeleRehab Advantage is a monitoring system that automates the generation of outcomes data. Patient information and session information is automatically transferred from the monitoring program to Outc...
... Clearly, the ISI Lexan ... versatile surgical table for lower ... orthopaedic, head and neck, and ... optional traction package gives you ...
MagaCell-Streptavidin is a streptavidin coupled to magnetizable cellulose/iron oxide particles...
Streptavidin A-Beads are polydisperse 1.8 m paramagnetic particles covalently coupled with streptavidin. The paramagnetic particles remain in solution over extended periods of time. Mixing is require...
Medicine Products: